JUBALYX Trademark
Trademark Overview
On Thursday, June 2, 2022, a trademark application was filed for JUBALYX with the United States Patent and Trademark Office. The USPTO has given the JUBALYX trademark a serial number of 97440272. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Thursday, November 21, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The JUBALYX trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
General Information
Serial Number | 97440272 |
Word Mark | JUBALYX |
Filing Date | Thursday, June 2, 2022 |
Status | 732 - THIRD EXTENSION - GRANTED |
Status Date | Thursday, November 21, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, April 11, 2023 |
Trademark Statements
Goods and Services | Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations |
Classification Information
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Friday, June 10, 2022 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | TEVA PHARMACEUTICALS USA, Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Parsippany, NJ 07054 |
Party Name | TEVA PHARMACEUTICALS USA, Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Parsippany, NJ 07054 |
Trademark Events
Event Date | Event Description |
Monday, June 6, 2022 | NEW APPLICATION ENTERED |
Friday, June 10, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Tuesday, February 28, 2023 | ASSIGNED TO EXAMINER |
Friday, March 3, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, March 22, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, April 11, 2023 | PUBLISHED FOR OPPOSITION |
Tuesday, April 11, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, June 6, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Monday, November 27, 2023 | SOU TEAS EXTENSION RECEIVED |
Monday, November 27, 2023 | SOU EXTENSION 1 FILED |
Monday, November 27, 2023 | SOU EXTENSION 1 GRANTED |
Wednesday, November 29, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, May 31, 2024 | SOU TEAS EXTENSION RECEIVED |
Friday, May 31, 2024 | SOU EXTENSION 2 GRANTED |
Friday, May 31, 2024 | SOU EXTENSION 2 FILED |
Thursday, June 13, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Thursday, November 21, 2024 | SOU TEAS EXTENSION RECEIVED |
Thursday, November 21, 2024 | SOU EXTENSION 3 FILED |
Thursday, November 21, 2024 | SOU EXTENSION 3 GRANTED |
Friday, November 22, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |